DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1620 De Clercq E. Clinical potential of the acyclic nucleoside phosphonates
cidofovir, adefovir, and tenofovir in treatment of
DNA virus and retrovirus infections. Clin Microbiol Rev, 2003,
16:569–596.
Delaney W, Yang H, Miller M, et al. Combinations of adefovir
with nucleoside analogs produce additive antiviral effects
against hepatitis B virus in vitro. Antimicrob Agents
Chemother, 2004, 48:3702–3710.
Dienstag JL. Benefits and risks of nucleoside analog therapy for
hepatitis B. Hepatology, 2009, 49:S112–S121.
Dienstag J, Goldin R, Heathcote E, et al. Histological outcome
during long-term lamivudine therapy. Gastroenterology, 2003,
124:105–117.
Dienstag J, Schiff E, Wright T, et al. Lamivudine as initial treatment
for chronic hepatitis B in the United States. N Engl J
Med, 1999, 341:1256–1263.
Eiland LS, Eiland EH. Zanamivir for the prevention of influenza
in adults and children age 5 years and older. Ther Clin Risk
Manag, 2007, 3:461–465.
Elion GB. History, mechanism of action, spectrum and selectivity
of nucleoside analogs. In: Antiviral Chemotherapy: New
Directions for Clinical Application and Research (Mills J,
Corey L, eds.), Elsevier, New York, 1986, pp. 118–137.
Elish D, Singh F, Weinberg JM. Therapeutic options for herpes
labialis. II: Topical agents. Cutis, 2004, 74:35–40.
Fried M, Shiffman M, Reddy K, et al. Peginterferon alfa-2a plus
ribavirin for chronic hepatitis C virus infection. N Engl J Med,
2002, 347:975–982.
Geary R, Henry S, Grillone L. Fomivirsen: Clinical pharmacology
and potential drug interactions. Clin Pharmacokinet,
2002, 41:255–260.
Ghosh S, Champlin RI, Englund J, et al. Respiratory syncytial
virus upper respiratory tract illnesses in adult blood and marrow
transplant recipients: Combination therapy with
aerosolized ribavirin and intravenous immunoglobulin. Bone
Marrow Transplant, 2000, 25:751–755.
Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir.
Clin Pharmacokinet, 1996, 31:1–8.
Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis,
1999, 19(suppl 1):17–24.
Glue P, Fang J, Rouzier-Panis R, et al. Pegylated interferonalpha2b:
Pharmacokinetics, pharmacodynamics, safety, and
preliminary efficacy data. Hepatitis C Intervention Therapy
Group. Clin Pharmacol Ther, 2000, 68:556–567.
Griffin S, Beales L, Clarke D, et al. The P7 protein of hepatitis
C virus forms an ion channel that is blocked by the antiviral
drug, amantadine. FEBS Lett, 2003, 535:34–38.
Hadziyannis SJ, Manesis EK, Papakonstantinou A. Oral ganciclovir
treatment in chronic hepatitis B virus infection: A pilot
study. J Hepatol, 1999, 31:210–214.
Hadziyannis S, Sette H, Morgan T, et al. Peginterferon-alpha2a
and ribavirin combination therapy in chronic hepatitis C: A
randomized study of treatment duration and ribavirin dose.
Ann Intern Med, 2004, 140:346–355.
Hadziyannis S, Tassopoulos N, Heathcote E, et al. Adefovir dipivoxil
for the treatment of hepatitis B e antigen–negative
chronic hepatitis B. N Engl J Med, 2003, 348:800–807.
Hadziyannis SJ, Vassilopoulos D. Telbivudine in the treatment of
chronic hepatitis B. Expert Rev Gastroenterol Hepatol, 2008,
2:13–22.
SECTION VII
CHEMOTHERAPY OF MICROBIAL DISEASES
Hayden F. Perspectives on antiviral use during pandemic
influenza. Phil Trans Soc Lond, 2001, 356:1877–1884.
Hayden F, Belshe R, Villanueva C, et al. Management of
influenza in households: A prospective, randomized comparison
of oseltamivir treatment with or without post-exposure
prophylaxis. J Infect Dis, 2004, 189:440–449.
Heathcote J, Shiffman M, Cooksley G, et al. Peginterferon alfa-
2a in patients with chronic hepatitis C and cirrhosis. N Engl J
Med, 2000, 343:1673–1680.
Hitchcock M, Jaffe H, Martin J, Stagg R. Cidofovir, a new agent
with potent anti-herpesvirus activity. Antiviral Chem
Chemother, 1996, 7:115–127.
Ho E, Lin D, Mendel D, Cihlar T. Cytotoxicity of antiviral
nucleotides adefovir and cidofovir is induced by the expression
of human renal organic anion transporter 1. J Am Soc Nephrol,
2000, 11:383–393.
Hong Z, Cameron C. Pleiotropic mechanisms of ribavirin antiviral
activities. Prog Drug Res, 2002, 59:41–69.
Infectious Disease Community of Practice, American Society of
Transplantation, Guidelines for the prevention and management
of infectious complications of solid organ transplantation:
Cytomegalovirus. Am J Transplant, 2004, 4(suppl 10): 51–58.
Jonas M, Kelly D, Mizerski J, et al. Clinical trial of lamivudine
in children with chronic hepatitis B. N Engl J Med, 2002,
346:1706–1713.
Kaiser L, Keene O, Hammond J, et al. Impact of zanamivir on
antibiotics use for respiratory events following acute influenza
in adolescents and adults. Arch Intern Med, 2000, 160:
3234–3240.
Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment
on influenza-related lower respiratory tract complications and
hospitalizations. Arch Intern Med, 2003, 163:1667–1672.
Keating G, Curran M. Peginterferon-alpha-2a (40 kDa) plus ribavirin:
A review of its use in the management of chronic hepatitis
C. Drugs, 2003, 63:701–730.
Keyser L, Karl M, Nafziger A, Bertino J Jr. Comparison of central
nervous system adverse effects of amantadine and rimantadine
used as sequential prophylaxis of influenza A in elderly nursing
home patients. Arch Intern Med, 2000, 160: 1485–1488.
Kimberlin D, Weller S, Whitley R, et al. Pharmacokinetics of
oral valacyclovir and acyclovir in late pregnancy. Am J Obstet
Gynecol, 1998, 179:846–851.
Kimberlin DW, Lin CY, Jacobs RF, et al,. Safety and efficacy of
high-dose intravenous acyclovir in the management of neonatal
herpes simplex virus infections. Pediatrics, 2001, 108:
230–238.
Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir
therapy on hearing in symptomatic congenital cytomegalovirus
disease involving the central nervous system: A randomized,
controlled trial. J Pediat, 2003, 143:16–25.
Kimberlin D, Rouse D. Clinical practice: Genital herpes. N Engl
J Med, 2004, 350:1970–1977.
Kimberlin D, Acosta E, Sanchez P, et al. Oseltamivir pharmacokinetics
(PK) in infants: Interim results from multicenter trial.
Paper presented at: 47th Annual Meeting of the Infectious
Diseases Society of America (IDSA); Philadelphia, PA; 2009.
Lai C, Yuen M, Hui C, et al. Comparison of the efficacy of
lamivudine and famciclovir in Asian patients with chronic hepatitis
B: Results of 24 weeks of therapy. J Med Virol, 2002,
67:334–338.